Overview

Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults

Status:
RECRUITING
Trial end date:
2028-05-01
Target enrollment:
Participant gender:
Summary
This randomized, crossover, placebo controlled clinical study will assess the efficacy and safety of a slow release form of levetiracetam (AGB101) in the treatment of cognitively normal adults by measuring change in several imaging measures over the course of a two week treatment period.
Phase:
PHASE2
Details
Lead Sponsor:
Johns Hopkins University
Collaborators:
AgeneBio
National Institute on Aging (NIA)
Treatments:
Levetiracetam
Sugars